Many institutions and researchers responded to the PAN Challenge call for papers last year, and even more are expected this year, said Daniel J. Klein, president and CEO of the Patient Access Network Foundation. He emphasized that this year’s Challenge is especially important because it can help reduce the financial hardships that many cancer patients often face.
Many institutions and researchers responded to the PAN Challenge call for papers last year, and even more are expected this year, said Daniel J. Klein, president and CEO of the Patient Access Network Foundation. He emphasized that this year’s Challenge is especially important because it can help reduce the financial hardships that many cancer patients often face.
Transcript (slightly modified)
Who are the typical applicants for the PAN Challenge call for papers and call for studies?
Well, we get papers from a number of sources. We make an effort to reach out to academic institutions, schools of public health, and researchers at medical schools, graduate schools, who are active in looking at health economic issues and looking at access issues. So we’ve had a very good response last year and we are expecting an even better response this year to the request for papers.
Why is the PAN Challenge important?
We think the PAN Challenge is especially important this year, because of the great deal of attention that the cost of prescription medications, brand medications, has gotten recently. And I think as we see higher and higher costs and more and more cost sharing, we know that patients are being impacted.
The leading cause of bankruptcy among people is related to high healthcare costs, and cancer patients are several times more likely to face bankruptcy than other patients. And they’re also more likely to face financial hardships, either being unable to pay their rent or being unable to pay their credit cards. We know that if we could reduce the out-of-pocket costs for cancer patients they’d be much less likely to face these kinds of financial hardships.
Contributor: Breaking the Cycle—RSAT Program Improving Reentry in Arizona
March 15th 2024Arizona is well suited to benefit from its 1115 demonstration waiver requested from CMS because it already has a robust justice-involved reentry initiative called the Residential Substance Abuse Treatment (RSAT) Program, which is emerging as an archetype of successful reentry programs that can serve as a template for other states to emulate.
Read More
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
An appeals court rules against the Pharmaceutical Research and Manufacturers of America in a 340B contract pharmacy dispute; for-profit investors’ acquisition of nursing homes has raised concerns about the quality of care provided in these facilities; President Joe Biden’s proposed budget for 2025 includes changes that would do away with the current system of biosimilar interchangeability.
Read More